Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Community Pharmacy

Overview

The patient's compliance to his medication therapy, and therefore the success of the treatment, is particularly related to his pharmacy management. Thus, the satisfaction of an individual in their interview with the pharmacist is a very important element. The pharmacist in his professional activity may have to manage patients with opioid related disorders. Pharmacist activity will result in the dispensing of opioid replacement therapy (ORT), single-use syringes, harm reduction kits and prevention advices for the reduction of toxicity and infection risks. Since the 1990s, the consumption of ORT has been steadily increasing. According to the OFDT (French Observatory of Drugs and Drug Addiction), the number of patients undergoing ORT is about 150 000 patients. Since high-dose buprenorphine is prescribed for approximately two-thirds of patients, it remains the most frequently prescribed ORT in France. Recently, a French association assisting drug users (ASUD – Auto-support des usagers de drogues) performed a study in Paris (20/07/2018 – 25/08/2018) to assess the delivery of opioid replacement therapies by community pharmacists. In this study, 71% of pharmacists refused to deliver opioid replacement therapies. The main reasons reported were security (56%) and activity saturation, meaning that pharmacists considered that they had too many patients using opioid drugs. In France, the refusal of a pharmacist to deliver drugs is a punishable offence. According to the Code of ethics of pharmacists, pharmacists must respect life and people without discrimination. Pharmacists have a low perception of patients suffering from opioid addiction. Another study performed by ASUD in 93 community pharmacies, showed that pharmacists used the term "toxicomaniacs" instead of "drug users". Most pharmacists had had a bad experience with drugs users, with physical and verbal aggressions. The conclusions of this study showed that pharmacists lacked knowledge of drug users and drug use. Pharmacists knew about harm reduction kits for opioid users (containing sterile syringes, needles, water, antiseptics, etc.) and had already opened them, but very few knew how to use them. More worryingly, some pharmacists did not understand the harm reduction strategies available It thus appears that community pharmacists have a difficult relationship with patient suffering of opioid related disorders, which can have an impact on patient's satisfaction. The objective of this study will be to assess the satisfaction of patients undergoing ORT regarding their management by community pharmacists.

Full Title of Study: “Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Community Pharmacy – SATISFY: a Cross-sectional Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: May 21, 2019

Detailed Description

Patients will be recruited in addiction departments, associations for risk management and general practitioners, and a paper questionnaire will be sent to the patients. The questionnaire is anonymous.

Interventions

  • Other: patients undergoing opioid replacement therapy
    • patients undergoing opioid replacement therapy

Arms, Groups and Cohorts

  • cohorte 1
    • patients undergoing opioid replacement therapy

Clinical Trial Outcome Measures

Primary Measures

  • Score of satisfaction
    • Time Frame: day 1
    • visual analogic scale (VAS) “Are you satisfied with your management by community pharmacists?” 0: not satisfied – 100: totally satisfied

Secondary Measures

  • Prevention tips given by the pharmacist: risk of infection, overdose, way of using drugs, adverse effects and drug interactions
    • Time Frame: day 1
    • yes/no
  • Services rendered by the pharmacist: sale of sterile equipment, management of soiled waste, dispensing of opioid replacement therapy
    • Time Frame: day 1
    • yes/no
  • Perception of the profile / behaviour of pharmacists: welcoming and open to discussion
    • Time Frame: day 1
    • VAS, 0: not at all – 100 : totally
  • Perception of the profile / behaviour of pharmacists: respect for confidentiality
    • Time Frame: day 1
    • VAS, 0: not at all – 100 : totally
  • Perception of the profile / behaviour of pharmacists: competent
    • Time Frame: day 1
    • VAS, 0: not at all – 100 : totally
  • opioid replacement therapy
    • Time Frame: day 1
    • name, dose, route
  • Number of physician consulted for the last 6 months
    • Time Frame: day 1
    • number
  • Number of community pharmacy consulted for the last 6 months
    • Time Frame: day 1
    • number
  • duration of opioid use disorder
    • Time Frame: day 1
    • number of years/months
  • Demographic information
    • Time Frame: day 1
    • : age, sex, study level, marital status, health care insurance, monthly income, type of housing

Participating in This Clinical Trial

Inclusion Criteria

  • Patient undergoing opioid replacement therapy Exclusion Criteria:

  • Age <18 years – Patient unable to understand or write in French

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Clermont-Ferrand
  • Collaborator
    • UFR de Pharmacie (Clermont-Ferrand)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David Balayssac, Principal Investigator, University Hospital, Clermont-Ferrand

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.